Stanojkovic, Ana (57729680500)Ana (57729680500)StanojkovicMrdovic, Igor (10140828000)Igor (10140828000)MrdovicTosic, Ivana (59753747100)Ivana (59753747100)TosicMatic, Dragan (25959220100)Dragan (25959220100)MaticSavic, Lidija (16507811000)Lidija (16507811000)SavicPetrovic, Jelena (57207943674)Jelena (57207943674)PetrovicCirkovic, Andja (56120460600)Andja (56120460600)CirkovicMilosevic, Aleksandra (56622640900)Aleksandra (56622640900)MilosevicSrdic, Milena (25936950900)Milena (25936950900)SrdicKostic, Natasa (59754111000)Natasa (59754111000)KosticRankovic, Ivan (57192091879)Ivan (57192091879)RankovicPetrusic, Igor (6603217257)Igor (6603217257)Petrusic2025-06-122025-06-122025https://doi.org/10.3390/jcm14082727https://www.scopus.com/inward/record.uri?eid=2-s2.0-105003597003&doi=10.3390%2fjcm14082727&partnerID=40&md5=ac3a0a66b842b5f062ce7ba5c49089c6https://remedy.med.bg.ac.rs/handle/123456789/478Background: Non-ST-segment elevation acute myocardial infarction (NSTEMI) represents a heterogeneous patient population with varying risks of adverse outcomes. The RISK-PCI score, initially developed for ST-segment elevation myocardial infarction (STEMI) patients, was evaluated for its prognostic value in NSTEMI patients undergoing percutaneous coronary intervention (PCI). Methods: A retrospective observational study of 242 NSTEMI patients treated with PCI at the Clinical Center of Serbia from June 2011 to June 2016 was conducted. The RISK-PCI score, incorporating clinical, echocardiographic, and angiographic variables, was calculated for each patient. The primary outcome was 30-day major adverse cardiovascular events (MACE). Secondary outcomes included individual components of MACE. Statistical analyses were performed to assess the predictive value of the RISK-PCI score. Results: The primary outcome of 30-day MACE occurred in 9.9% of patients. Independent predictors of 30-day MACE included age > 75 years, glucose ≥ 6.6 mmol/L, creatinine clearance < 60 mL/min, and post-procedural TIMI flow < 3. The RISK-PCI score demonstrated good discrimination for 30-day MACE (AUC = 0.725). Patients stratified into the very high-risk group (RISK-PCI score ≥ 7) had significantly higher risks of 30-day MACE (29.4%). Conclusions: The RISK-PCI score effectively stratifies NSTEMI patients by their risk of 30-day MACE, identifying a very high-risk subgroup that may benefit from closer monitoring and tailored interventions. External validation on larger cohorts is recommended to confirm these findings. © 2025 by the authors.acute myocardial infarctionMACEnon-st-segment elevationrisk stratificationRISK-PCI score